A Registered Cohort Study of Immune-Mediated Neuropathies

December 28, 2021 updated by: Ning Wang, MD., PhD., First Affiliated Hospital of Fujian Medical University
This study will provide further insights into the natural course of the disease about Immune-Mediated Neuropathies including clinical features,progression, related antibody spectrum and drug treatment effect.

Study Overview

Study Type

Observational

Enrollment (Anticipated)

1000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Beijing
      • Beijing, Beijing, China
        • Recruiting
        • Beijing Tiantan Hospital, Capital Medical University
        • Contact:
          • Zaiqiang Zhang
        • Principal Investigator:
          • Zaiqiang Zhang, PhD
    • Fujian
      • Fuzhou, Fujian, China, 350005
        • Not yet recruiting
        • Department of Neurology,First Affiliated Hospital of Fujian Medical University
        • Principal Investigator:
          • Wang MD Ning, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Patients with GBS,CIDP,MMN who are diagnosied in the First Affiliated Hospital of Fujian Medical Universtiy and Beijing Tiantan Hospital, Capital Medical University by two neurolgists

Description

Inclusion Criteria:

- 1. Outpatient or inpatient 2. Meet the diagnostic criteria of various inflammatory peripheral neuropathy. 3. Voluntary participation and informed consent signed by the applicant or his/her family.

4. Age 18 or above

Exclusion Criteria:

  1. Severe complications
  2. Poor prognosis (<1 year survival)
  3. Severe mental disorder and inability to cooperate with the examination.
  4. Age less than 18

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The correlation between clinical phenotypes and Serum antibodies
Time Frame: from date of enrollment until the date of death from any cause,assessed up to 20 years
Different clinical subtypes of GBS and CIDP have different course and prognosis.It may be related to different serum antibodies.
from date of enrollment until the date of death from any cause,assessed up to 20 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 29, 2020

Primary Completion (Anticipated)

January 19, 2022

Study Completion (Anticipated)

January 19, 2025

Study Registration Dates

First Submitted

February 28, 2020

First Submitted That Met QC Criteria

February 28, 2020

First Posted (Actual)

March 3, 2020

Study Record Updates

Last Update Posted (Actual)

December 30, 2021

Last Update Submitted That Met QC Criteria

December 28, 2021

Last Verified

December 1, 2021

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Inflammatory Demyelinating Polyneuropathy

3
Subscribe